ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CEL Celadon Pharmaceuticals Plc

61.00
1.50 (2.52%)
22 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Celadon Pharmaceuticals Plc LSE:CEL London Ordinary Share GB00BDQYGP38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 2.52% 61.00 57.00 65.00 61.00 59.50 59.50 12,246 14:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 149k -7.14M -0.1082 -5.64 39.26M

Celsis International - Rule 8 Disclosure

29/05/1998 5:21pm

UK Regulatory


RNS No 1931p
CELSIS INTERNATIONAL PLC


                                       Date of Disclosure 29/05/98..............

               DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3
                 OF THE CITY CODE ON TAKE-OVERS AND MERGERS

Date of dealing 29/05/98............

Dealing in CELSIS INT PLC.....................(name of company)

(1)  Class of securities (eg ordinary shares) ORD 1P.....................

(2)  Amount bought                  Amount sold             Price per unit
          50,000                                                45P


(3)  Resultant total of the same class owned or controlled
(and percentage of class) 2,700,000............................. (2.71%)

(4)  Party making disclosure CORLUY & CO....................................

(5)  EITHER (a) Name of purchaser/vendor (Note 1) N/A........................
     OR     (b) if dealing for discretionary client(s), name of fund management
                organisation
............................CORLUY VIP ACC.................................

(6)  Reason for disclosure (Note 2)  
     (a) associate of (i)  offeror (Note 3)                             NO
                      (ii) offeree company                              NO

Specify which category or categories of associate (1-8 overleaf)....N/A........

If category (8), explain.........N/A............................................

................................................................................
     (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more
         of the class of relevant securities dealt in)                  YES

Signed, for and on behalf of the party named in (4) above......N/A..............

(Also print name of signatory) S. CASTELEYN...................................

Telephone and extension number 00 32 3 230 1005................................

Note 1.  Specify owner, not nominee or vehicle company.  If relevant, also
identify controller of owner, eg where an owner normally acts on instructions of
a controller.

Note 2.  Disclosure might be made for more than one reason; if so, state all
reasons.

Note 3.  Specify which offeror if there is more than one.

Note 4.  When an arrangement exists with any offeror, with the offeree company
or with an associate of any offeror or of the offeree company in relation to
relevant securities, details of such arrangement must be disclosed, as required
by Note 6 on Rule 8............................................................
...............................................................................
...............................................................................

For full details of disclosure requirements, see Rule 8 of the Code.  If in
doubt, contact the Panel on Take-overs and Mergers, Tel. No: 0171-382 9026.

END



DCCGLGZKVLRLRMM


1 Year Celadon Pharmaceuticals Chart

1 Year Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

Your Recent History